You are here: Industry Insights > teva

News List

Teva Wins FDA Nod for TRISENOX (arsenic trioxide) Injection for First Line Treatment of Acute Promye biospace
January 16, 2018
Teva Announces U.S. FDA Approval of TRISENOX (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia
Teva Board Members Face 50% Pay Cut biospace
January 12, 2018
To describe Teva Pharmaceutical Industries as “embattled” is a bit of an understatement.
Teva and Alder sign global licence agreement on anti-CGRP therapy pharmaceutical-technology
January 11, 2018
Teva Pharmaceuticals International has entered a global licence agreement with Alder BioPharmaceuticals for anti-calcitonin gene-related peptide (CGRP) antibodies and their usage techniques.
GlaxoSmithKline CEO Replaced 50 Top Managers, Lured Execs From Google, Novartis and Teva biospace
January 11, 2018
GlaxoSmithKline Chief Executive Officer Emma Walmsley is not done reshaping her leadership team as she continues to overhaul the company’s pharmaceutical division
Teva, Alder BioPharma Forge $200M Anti-CGRP-Based Therapy Pact biospace
January 09, 2018
Teva Announces Global License Agreement with Alder BioPharmaceuticals in the Field of Anti-CGRP-Based Therapy
Teva Announces Exclusive Launch of Generic Version of Reyataz americanpharmaceuticalreview
December 28, 2017
Teva Pharmaceutical announced the exclusive launch of a generic version of Reyataz (atazanavir) capsules in the U.S.
Teva Sees Approval at Finish Line for Anti-CGRP Migraine Treatment biospace
December 25, 2017
With a priority review voucher in hand, Teva Pharmaceuticals is expecting the U.S. Food and Drug Administration to rule on its new migraine treatment fremanezumab by June.
Teva’s anti-CGRP drug under review for migraine pharmatimes
December 20, 2017
US regulators are now reviewing Teva Pharmaceutical’s experimental anti-CGRP therapy fremanezumab for the preventive treatment of migraine, and have also granted the drug a fast track designation for the prevention of cluster headache.
Teva Announces Restructuring Plan, Cuts 25% of Workforce Worldwide americanpharmaceuticalreview
December 18, 2017
Teva Pharmaceutical announced a restructuring plan to significantly reduce its cost base, which includes laying off 14,000 employees worldwide.
Rumours have it that Teva job cut could be in the range of 10,000 pharmafile
December 12, 2017
Only last month, the story broke that Teva was looking to cut away a number of employees, the rumours have now intensified with reports suggesting the number could be in the region of 10,000.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page